May 30, 2025 08:00 AM EDTUpdated 10:00 AM

Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients

Lei Lei Wu

News Reporter

Adding Pfizer’s BRAF inhibitor Braftovi to a cocktail of cancer drugs cut the risk of death by half for certain colorectal cancer patients, according to …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

VP, Clinical Development / CMO / CDO‬ ‭ (Stealth Portfolio Company)

Autonomy Bio Inc.

San Francisco, CA 94107, USA

FDA approves Moderna’s next-gen Covid vaccine, with limits on most healthy people

Summit’s disappointing survival readout raises stakes for full data

Summit says bispecific misses overall survival in closely-watched lung cancer study

Gilead, Merck reveal 'practice-changing' data for Trodelvy-Keytruda combo in aggressive breast cancer

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Pfiz­er's Braftovi com­bo dou­bles sur­vival time for some col­orec­tal can­cer pa­tients

News Reporter

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pfizer's Braftovi combo doubles survival time for some colorectal cancer patients